Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline

Executive Summary

Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.

You may also be interested in...



Ninlaro Positive In Non-Transplant MM Maintenance

Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Eyes On Divestments, Revised Guidance Ahead Of Takeda's Q1

As Takeda prepares to report its first full quarter post-Shire next week, eyes will be on further strategic divestments and trends that could lead to a raising of guidance in Q2.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel